{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:46:19Z","timestamp":1791895579384,"version":"4.3.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recurrent adult ependymomas lack standard systemic therapies and evidence on chemotherapy and targeted agents is limited. This study aimed to retrospectively evaluated outcomes of systemic therapies, including targeted combinations, in a real-world cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with intracranial or spinal ependymoma treated at our institution between 2013 and 2025 who received at least one systemic line at recurrence were included. Tumor response was assessed according to RANO criteria. Primary endpoints were disease control rate (DCR) and progression-free survival (PFS). Secondary endpoints were overall survival from the start of the first line treatment (OSt) and overall survival from diagnosis (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 47 patients, 12 received systemic therapy at recurrence. The median follow up duration for the entire cohort was 28.3 months. Temozolomide (TMZ) was the most commonly used agent (n=12). TMZ monotherapy achieved a DCR of 57% with 6- and 12-month PFS rates of 85.7% and 57.1%, respectively. Targeted therapy was administered to 7 patients: the TMZ-Lapatinib combination provided limited benefit (DCR 33%, median PFS 2.9 months), bevacizumab-based regimens showed variable efficacy; bevacizumab alone achieved a DCR of 33% with one case of prolonged stabilization (&amp;gt;58 months), while bevacizumab plus fotemustine yielded a PFS of 14.1 months. Treatments were generally well tolerated, with limited grade 3 toxicities. Sequential systemic therapy, up to five lines, was feasible in selected cases. Median OSt was not reached; 12-month OS was 66.7%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world analysis indicates that temozolomide is feasible and associated with disease stabilization in selected patients, while bevacizumab-based combinations showed signals of clinical activity in recurrent adult ependymomas. Prospective, biomarker-driven multicenter trials are warranted to optimize systemic strategies in this rare disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1748353","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:33:45Z","timestamp":1771392825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Marta","family":"Maccari","sequence":"first","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova","place":["Padova, Italy"]},{"name":"Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosio","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova","place":["Padova, Italy"]},{"name":"Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Caccese","sequence":"additional","affiliation":[{"name":"Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Padovan","sequence":"additional","affiliation":[{"name":"Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Guerriero","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology Unit, Padova University Hospital","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Librizzi","sequence":"additional","affiliation":[{"name":"Padova Neuroscience Center (PNC), University of Padova","place":["Padova, Italy"]},{"name":"Neuroradiology Unit, Padova University Hospital","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Pintacuda","sequence":"additional","affiliation":[{"name":"Radiology Unit, Veneto Institute of Oncology IOV-IRCCS","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Bellu","sequence":"additional","affiliation":[{"name":"Radiotherapy Unit, IOV-IRCCS Veneto Institute of Oncology","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Fiorentino","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, General Regional Hospital F. Miulli, (BA)","place":["Acquaviva delle Fonti, Italy"]},{"name":"Department of Medicine, LUM University","place":["Casamassima, BA, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Volpin","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Padova University Hospital","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Ius","sequence":"additional","affiliation":[{"name":"Academic Neurosurgery, Department of Neurosciences, University of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Chioffi","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Padova University Hospital","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Denaro","sequence":"additional","affiliation":[{"name":"Academic Neurosurgery, Department of Neurosciences, University of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[{"name":"Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.09.001","article-title":"Radial glia cells are candidate stem cells of ependymoma","volume":"8","author":"Taylor","year":"2005","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noae047","article-title":"CBTRUS statistical report: American brain tumor association & NCI neuro-oncology branch adolescent and young adult primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20132020","volume":"26","author":"Price","year":"2024","journal-title":"Neuro-Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro-Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3171\/2008.9.JNS08117","article-title":"Incidence patterns for ependymoma: a Surveillance, Epidemiology, and End Results study: Clinical article","volume":"110","author":"McGuire","year":"2009","journal-title":"J Neurosurg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e13068","DOI":"10.1111\/bpa.13068","article-title":"Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond","volume":"32","author":"Kresbach","year":"2022","journal-title":"Brain Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups","volume":"27","author":"Pajtler","year":"2015","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12866","article-title":"cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors","volume":"30","author":"Ellison","year":"2020","journal-title":"Brain Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01260-w","article-title":"Ependymoma: evaluation and management updates","volume":"24","author":"Rud\u00e0","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12050","article-title":"Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system","volume":"23","author":"Raghunathan","year":"2013","journal-title":"Brain Pathol Zurich Switz"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-012-0941-4","article-title":"A prognostic gene expression signature in infratentorial ependymoma","volume":"123","author":"Wani","year":"2012","journal-title":"Acta Neuropathol (Berl)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20074","article-title":"A multicenter study of the prognosis and treatment of adult brain ependymal tumors","volume":"100","author":"Reni","year":"2004","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2005.102.4.0629","article-title":"Is gross-total resection sufficient treatment for posterior fossa ependymomas","volume":"102","author":"Rogers","year":"2005","journal-title":"J Neurosurg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm046","article-title":"Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients","volume":"130","author":"Metellus","year":"2007","journal-title":"Brain J Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq047","article-title":"Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients","volume":"12","author":"Metellus","year":"2010","journal-title":"Neuro Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-018-3570-4","article-title":"Surgical management and long-term outcome of intracranial subependymoma","volume":"160","author":"Varma","year":"2018","journal-title":"Acta Neurochir (Wien)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox166","article-title":"EANO guidelines for the diagnosis and treatment of ependymal tumors","volume":"20","author":"Rud\u00e0","year":"2018","journal-title":"Neuro-Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2020.05.045","article-title":"Postoperative radiotherapy for WHO grade II-III intracranial ependymoma in adults: An intergroup collaborative study (KROG 18-06\/KNOG 18-01)","volume":"150","author":"Wee","year":"2020","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1023\/a:1014442106111","article-title":"Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure","volume":"56","author":"Oya","year":"2002","journal-title":"J Neurooncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.06.002","article-title":"Postoperative radiation therapy for grade II and III intracranial ependymoma","volume":"61","author":"Mansur","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1254-8","article-title":"Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis","volume":"115","author":"Ghia","year":"2013","journal-title":"J Neurooncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2013.07.009","article-title":"An overview of the management of adult ependymomas with emphasis on relapsed disease","volume":"25","author":"Iqbal","year":"2013","journal-title":"Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/PAS.0000000000001669","article-title":"Survival and prognostic factors of adult intracranial ependymoma: A single-institutional analysis of 236 patients","volume":"45","author":"Zhao","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov167","article-title":"Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study","volume":"18","author":"Rud\u00e0","year":"2016","journal-title":"Neuro-Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24524","article-title":"Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma","volume":"115","author":"Chamberlain","year":"2009","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21110","article-title":"A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia","volume":"104","author":"Brandes","year":"2005","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa240","article-title":"A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma","volume":"23","author":"Gilbert","year":"2021","journal-title":"Neuro-Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1023\/a:1006394407245","article-title":"Chemotherapy for advanced CNS ependymoma","volume":"45","author":"Gornet","year":"1999","journal-title":"J Neurooncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11060-015-1764-7","article-title":"An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)","volume":"123","author":"DeWire","year":"2015","journal-title":"J Neurooncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12885-016-2323-0","article-title":"Chemotherapy for intracranial ependymoma in adults","volume":"16","author":"Gramatzki","year":"2016","journal-title":"BMC Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0b013e3181c1df34","article-title":"Bevacizumab for recurrent ependymoma","volume":"73","author":"Green","year":"2009","journal-title":"Neurology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1748353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:30:55Z","timestamp":1771932655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1748353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1748353"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1748353","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1748353"}}